What you will hear: The Fight for Justice in Mass Torts
In this episode of Trial Lawyer View, Jason Lazarus is joined by Michael B. Lynch, Esq. of The Michael Brady Lynch Firm to explore the evolving world of mass tort litigation. Drawing from over two decades of experience, Lynch discusses everything from Ozempic and Roundup to the troubling use of the Texas Two-Step bankruptcy strategy.
Lynch offers a powerful perspective on pharmaceutical accountability, the dangers of prioritizing profit over patient safety, and how attorneys can still deliver personalized representation in a virtual legal environment. He also shares advice for emerging trial lawyers and a call to action for upholding justice in the face of corporate complexity.
“They're putting profits before consumers.”
What you’ll learn:
-How Michael Lynch’s first mass tort shaped his legal philosophy
-What Ozempic lawsuits mean for the future of drug litigation
-Why the Texas Two-Step strategy is undermining the justice system
-The ongoing fight for accountability in Roundup cases
-How smaller firms can deliver powerful, personal client care
-Why the rise of virtual law practices is here to stay
-The impact of venture capital on the litigation landscape
-What new trial lawyers should prioritize in their careers
-How to adapt as a trial lawyer in a tech-driven world
This conversation is a candid look at what it takes to fight—and win—against corporate interests in today’s mass tort system.
Listen now → https://triallawyerview.com/podcast
Subscribe to the Peak Practice LinkedIn Newsletter for more expert insights.
Chapters:
00:00 – Journey into Mass Tort Litigation
02:47 – The Impact of New Drugs: Ozempic and Its Risks
06:04 – The Texas Two-Step Bankruptcy Strategy
11:47 – Challenges in Roundup Litigation and Consumer Safety
25:18 – Navigating Corporate Giants in Mass Torts
30:33 – Strategies for Emerging Trial Lawyers
40:32 – The Evolution of Virtual Law Practices
46:35 – The Role of a Mass Tort Attorney Today
